查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006423

生物銀行市場：2026-2032年全球市場預測（按服務類型、生物樣本庫類型、檢體類型、應用程式和最終用戶分類）

Biobanking Market by Offering, Biobank Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生物銀行市場價值將達到 813.7 億美元，到 2026 年將成長至 908.6 億美元，到 2032 年將達到 1820.3 億美元，複合年成長率為 12.19%。

主要市場統計數據
基準年 2025 813.7億美元
預計年份：2026年 908.6億美元
預測年份 2032 1820.3億美元
複合年成長率 (%) 12.19%

一個創新的生物銀行平台正在推動全球科學界在疾病研究和個人化醫療領域取得突破。

生物樣本庫已成為現代生命科學研究的基礎基礎設施，它不僅保存了珍貴的生物檢體，還能同時收集相關關鍵數據。隨著精準醫療的應用範圍不斷擴大，研究人員越來越依賴管理完善的檢體庫來深入了解疾病機制和治療反應。檢體完整性和資料品質之間的這種共生關係凸顯了建構穩健的生物銀行系統的戰略重要性，這類系統需要將先進的保存技術與全面的資訊科學能力無縫整合。

模式轉移正在推動生物銀行從傳統的儲存設施向整合的、數據驅動的平台發展，這將塑造未來的研究。

過去十年，創新為生物銀行帶來了許多變革。最初，重點在於實體儲存基礎設施，但如今，為了提升效率和擴充性，人們正在採用一套整合技術生態系統。自動化檢體搜尋系統減少了人工操作錯誤，而人工智慧驅動的分析也開始揭示檢體利用模式，有助於策略決策。

2025 年美國關稅調整評估：不斷擴大的成本結構和供應鏈趨勢對生物銀行營運和全球合作模式的影響。

隨著全球供應鏈因美國提案的2025年關稅調整而重組，生物銀行產業面臨複雜的挑戰與機會。一方面，進口耗材和設備的關稅增加可能會推高營運成本，促使相關人員重新評估籌資策略。另一方面，國內生產合作夥伴可能會面臨需求激增，這很可能推動本地產能擴張，並促進研究機構與供應商之間建立新的合作關係。

全面的細分分析揭示了生物銀行市場的多樣化促進因素，涵蓋設備、服務、軟體解決方案、檢體類型、應用程式和最終用戶。

對生物銀行產品的分析揭示了其由三個要素構成的結構：有形基礎設施、專業服務和數位化管理平台。在產品類型，先進的設備和耗材構成了檢體保存的基礎。自動化儲存系統簡化了檢體檢索流程，低溫儲存單元則維持著超低溫環境。諸如培養箱、離心機、冷藏庫和冷凍庫等必要的實驗室設備與這些核心資產相輔相成，而專門設計的運輸和包裝單元則在運輸過程中保護檢體。此外，一系列旨在最佳化檢體活性並符合監管要求的耗材也進一步完善了這些工具。同時，基於服務的模式正在不斷發展，以涵蓋整體生物銀行工作流程。這包括將知情同意和法律規範整合到計劃通訊協定中、先進的資料管理和生物資訊解決方案、端到端的檢體採集、處理和儲存服務，以及確保無縫儲存鏈的專用運輸和物流網路。在這些實體和服務元件之上，也建構了一個軟體平台，提供集中式監控功能。這使得強大的實驗室資訊管理系統和分析儀表板能夠匯總元資料，從而支援戰略決策。

一份策略性的區域展望報告，重點介紹了美洲、歐洲、中東和非洲以及亞太地區不斷擴大的生物銀行系統的趨勢和成長要素。

在美洲，北美成熟的研究中心持續推動生物銀行領域的創新。這些中心擁有先進的設施，並得到雄厚的公共和私人資金支持，充分利用了尖端的低溫運輸技術和完善的資料管理基礎設施。這種成熟的環境促進了學術機構、生技公司和監管機構之間的合作網路，致力於推動精準醫療計畫。同時，在拉丁美洲的新興市場，加強生物樣本庫能力的投資正在增加，以支持區域人口調查並應對地方性健康挑戰。戰略夥伴關係和技術轉移協議變得至關重要，使相關人員能夠在保持全球品質標準的同時，充分利用多樣化的本地檢體資源。

引領生物銀行創新者推動技術創新：透過商業策略和合作專案改變樣本儲存；分析和物流解決方案。

產業領導企業正透過對自動化、資訊學和策略合作的定向投資，展現出推動生物銀行建置的明確決心。例如，一家知名儀器製造商透過整合機器人和雲端監控系統，提升了低溫儲存的自動化程度，實現了即時警報和預測性維護。另一位分子樣本製備專家則在其產品組合中新增了一套全面的數據分析解決方案，以最佳化工作流程並簡化監管報告流程。這些技術提供者正在為檢體完整性和營運透明度樹立新的標竿。

為生物銀行相關人員提供的實用藍圖：提高營運效率、促進創新、加強監管合規性、擴大策略夥伴關係。

為了在不斷發展的生物銀行領域保持競爭優勢，產業領導者應優先採用先進的自動化和數位化技術。將機器人儲存和檢索系統與集中式分析平台結合，既能提高處理能力，又能最大限度地減少人為錯誤。此外，整合機器學習工具來預測設備維護需求並簡化檢體追蹤流程，可以增強營運的韌性。

採用穩健的調查方法，結合定性和定量方法；透過一手資料收集和嚴格的檢驗過程，確保可靠性和深度。

本報告的調查方法結合了定性和定量方法，旨在提供全面且客觀的見解。初步的二手資料研究廣泛查閱了學術文獻、行業期刊和監管指南，以建立對當前生物銀行實踐和新興趨勢的基本理解。這項桌上研究有助於發展一手研究的工具和訪談通訊協定。

生物銀行發展歷程概述：重點在於策略挑戰、塑造研究環境的協作創新以及面向未來的解決方案

生物銀行領域持續發展，始終是轉化研究和精準醫療計畫的基石。先進的保存技術、資訊平台和服務導向模式的整合正在重塑傳統的工作流程，從而實現更有效率、更可靠的檢體管理。此外，虛擬儲存庫和分散式網路的整合正在拓展合作研究的範圍，並促進整個研究界的創新。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物銀行市場：依產品/服務分類

  • 產品
    • 生物銀行設備
      • 自動化樣品儲存系統
      • 低溫儲存系統
      • 培養箱和離心機
      • 冷藏庫和冷凍庫
      • 檢體運送及包裝單元
    • 消耗品
  • 服務
    • 同意獲取和監管合規服務
    • 資料管理與生物資訊學
    • 檢體採集和處理服務
    • 檢體儲存服務
    • 檢體運輸及物流
  • 軟體

第9章：以生物樣本庫類型分類的生物銀行市場

  • 物理生物樣本庫
  • 虛擬生物樣本庫

第10章：檢體類型分類的生物銀行市場

  • 血
    • 電漿
    • 血清
    • 全血
  • 細胞
  • DNA／RNA
  • 組織

第11章：生物銀行市場：依應用領域分類

  • 診斷和治療
  • 藥物發現與臨床研究

第12章：生物銀行市場：依最終使用者分類

  • 學術和研究機構
  • 合約研究組織（CRO）
  • 政府和公共衛生機構
  • 醫院/臨床檢查室
  • 製藥和生物技術公司

第13章：生物銀行市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：生物銀行市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物銀行市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生物銀行市場

第17章：中國生物銀行市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ASKION GmbH
  • Avantor, Inc.
  • Azenta Life Sciences, Inc.
  • BioKryo
  • BioLife Solutions, Inc.
  • Charles River Laboratories International, Inc.
  • Cryoport Systems, LLC
  • Cureline, Inc.
  • FIND
  • Firalis Molecular Precision
  • Greiner Bio-One International GmbH
  • Hamilton Company
  • LGC Biosearch Technologies
  • Merck KGaA
  • PHC Corporation
  • Qiagen NV
  • Sampled
  • Sopachem BV
  • SPT Labtech Ltd
  • STEMCELL Technologies Inc.
  • Taylor-Wharton
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.
  • US Biolab Corporation, Inc.
  • VigiSolvo
Product Code: MRR-961BA04A2DC3

The Biobanking Market was valued at USD 81.37 billion in 2025 and is projected to grow to USD 90.86 billion in 2026, with a CAGR of 12.19%, reaching USD 182.03 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 81.37 billion
Estimated Year [2026] USD 90.86 billion
Forecast Year [2032] USD 182.03 billion
CAGR (%) 12.19%

Innovative Biobanking Foundations Driving Breakthroughs in Disease Research and Personalized Healthcare Across Global Scientific Communities

Biobanks have emerged as foundational infrastructures in modern life sciences research, preserving precious biological specimens while capturing critical associated data. As the scope of precision medicine expands, researchers increasingly rely on well-curated sample repositories to unlock insights into disease mechanisms and therapeutic responses. This symbiotic relationship between sample integrity and data quality underscores the strategic importance of robust biobanking systems that seamlessly integrate advanced storage technologies with comprehensive informatics capabilities.

In recent years, interdisciplinary collaborations have accelerated innovation across the biobanking landscape. Cutting-edge cryogenic storage platforms now interface with digital management solutions, enabling real-time monitoring of specimen viability and metadata analytics. Consequently, research institutions and industry stakeholders can mitigate variability, enhance reproducibility and accelerate discovery cycles. These technological synergies have redefined best practices, elevating biobanks from passive repositories to dynamic research hubs.

Looking ahead, evolving regulatory frameworks and ethical considerations will further shape the trajectory of biobanking operations. With an emphasis on consent management, data privacy and interoperability standards, biobanks are poised to become pivotal enablers of decentralized clinical trials and population-scale studies. This introductory overview sets the stage for a deeper exploration of the transformative trends driving the next frontier of biobanking excellence.

Global health initiatives are increasingly leveraging biobanking networks to support large-scale population studies and accelerate responses to public health crises. By integrating multi-omic datasets with patient demographics, researchers can identify biomarkers and therapeutic targets with greater precision. Additionally, partnerships between academic consortia, healthcare providers and private sector innovators have intensified, fostering knowledge exchange and accelerating translational pipelines. Consequently, the role of biobanks extends beyond preservation; they are now instrumental in orchestrating collaborative research efforts that span continents and disciplines, ultimately contributing to more resilient healthcare systems and improved patient outcomes.

Paradigm Shifts Catalyzing the Evolution of Biobanking from Conventional Storage Facilities to Integrated Data-Driven Platforms Shaping Future Research

Innovation has propelled biobanking through several transformative shifts over the last decade. Initially focused on physical storage infrastructure, the discipline now embraces an ecosystem of integrated technologies that promote efficiency and scalability. Automated sample retrieval systems have reduced manual handling errors, while artificial intelligence-driven analytics have begun to uncover patterns in specimen utilization that inform strategic decision making.

Moreover, the rise of virtual biobanks has redefined traditional paradigms by enabling remote access to digital representations of biological materials. This shift has fostered cross-institutional collaborations, as researchers can now query standardized datasets without logistical constraints. Simultaneously, the emergence of cloud-based platforms has facilitated streamlined data governance, providing secure channels for consent management and multi-modal integration of genomic, clinical and environmental data.

In addition, service-oriented models have gained prominence, with specialized providers offering end-to-end solutions spanning sample collection, processing, storage and transport. This diversification has allowed organizations to tailor biobanking strategies to project-specific requirements, optimizing resource allocation and reducing time to insight. As the biobanking sector continues to mature, these foundational shifts will underpin future innovations and guide sustainable growth across the global research landscape.

Emerging trends in sustainability and environmental responsibility are also reshaping biobanking practices. Institutions are adopting energy-efficient ultra-low temperature freezers and exploring renewable energy integration within cold storage facilities to minimize carbon footprints. In parallel, digital twin models of storage environments enable simulation of energy usage patterns to optimize resource allocation. As a result, biobanks are not only improving operational efficiency but also aligning with corporate social responsibility goals, reinforcing their commitment to sustainable science and long-term viability in a resource-conscious world.

Assessment of United States Tariff Adjustments in 2025 Expanding Cost Structures and Supply Chain Dynamics Impacting Biobanking Operations and Global Collaboration Models

As global supply chains recalibrate in response to the United States' proposed 2025 tariff adjustments, the biobanking community faces a complex set of challenges and opportunities. On one hand, increased duties on imported consumables and equipment could elevate operational costs, prompting stakeholders to reevaluate procurement strategies. On the other hand, domestic manufacturing partners may experience a surge in demand, driving expansion of local production capabilities and fostering new alliances between research institutions and suppliers.

Furthermore, shifting trade policies have underscored the importance of supply chain resilience. In response, biobanks are diversifying vendor portfolios and exploring nearshoring options to mitigate the risk of prolonged lead times and geopolitical disruptions. At the same time, strategic stockpiling of critical reagents and consumables has emerged as a proactive measure to ensure continuity of operations, particularly for long-term cohort studies and high-throughput variant screening projects.

In addition to cost implications, regulatory harmonization efforts are gaining momentum. Collaborative dialogues between public health agencies and industry consortia aim to streamline cross-border logistics, reduce documentation burdens and expedite customs clearance processes. Consequently, the sector can maintain high standards of sample integrity while adapting to evolving trade environments. Taken together, these dynamics will redefine procurement frameworks and operational priorities across the biobanking value chain.

As organizations navigate these tariff-induced cost pressures, many are exploring performance-based contracts with suppliers to achieve negotiated pricing and guarantee supply continuity. Simultaneously, government incentive programs and public-private funding initiatives aim to offset increased duties, offering grants and tax credits for domestic equipment investments. These support mechanisms foster local manufacturing expansion and encourage stakeholders to engage in long-term infrastructure planning.

Comprehensive Segmentation Insights Revealing Diverse Biobanking Market Drivers Spanning Equipment, Services, Software Solutions, Specimen Types, Applications and End Users

An examination of biobanking offerings reveals a tripartite structure encompassing tangible infrastructure, specialized services and digital management platforms. Within the product category, sophisticated equipment and consumables form the backbone of specimen preservation. Automated storage systems streamline sample retrieval while cryogenic storage units maintain ultra-low temperature integrity. Essential laboratory instruments such as incubators, centrifuges, refrigerators and freezers complement these core assets, and purpose-designed transport and packaging units safeguard specimens during transit. Complementing these tools is an array of consumables engineered for optimal sample viability and regulatory compliance. Meanwhile, service-based models have evolved to address the full spectrum of biobanking workflows: consent and regulatory frameworks embedded within project protocols; advanced data management and bioinformatics solutions; end-to-end sample collection, processing and storage services; and dedicated transport and logistics networks that ensure seamless chain of custody. Layered atop these physical and service components, software platforms provide centralized oversight, offering robust laboratory information management systems and analytical dashboards that aggregate metadata to inform strategic decisions.

Diving deeper into biobank typologies, traditional physical repositories coexist with emerging virtual environments. The former emphasizes on-site specimen curation and long-term archiving, whereas the latter leverages digital interfaces and distributed data links to facilitate remote access and collaborative research. This dual approach enables institutions to adapt storage strategies to project demands, balancing in-house capabilities with networked sharing models.

Regarding specimen categories, whole blood and its derivatives-plasma and serum-form a critical segment, alongside discrete cell lines, extracted DNA and RNA preparations, and a diverse array of tissue samples. Each sample type presents unique handling and preservation challenges, driving tailored protocol development.

In terms of application, biobanks support both diagnostics and therapeutics through patient specimen repositories and serve as foundational resources for drug discovery and clinical research initiatives. This breadth of use cases underscores the sector's capacity to bridge translational gaps.

Finally, a wide spectrum of end users relies on these segmented offerings. Academic and research institutions pursue foundational science, whereas contract research organizations prioritize streamlined trial operations. Government and public health agencies demand stringent compliance, clinical laboratories and hospital systems integrate repositories into care pathways, and pharmaceutical and biotechnology companies harness biobanking assets to accelerate pipeline development.

Strategic Regional Perspectives Highlighting Trends and Growth Levers Across Americas, Europe Middle East Africa and Asia-Pacific in the Expanding Biobanking Ecosystem

Throughout the Americas, established research hubs in North America continue to drive innovation in biobanking. Cutting-edge facilities leverage state-of-the-art cold chain technologies and comprehensive data management infrastructures, underpinned by robust funding from public and private sources. This mature environment fosters collaborative networks between academic centers, biotechnology firms and regulatory bodies focused on advancing precision medicine initiatives. At the same time, emerging markets in Latin America are increasingly investing in biobank capabilities to support regional population studies and address endemic health challenges. As a result, strategic partnerships and technology transfer agreements have become pivotal, enabling stakeholders to capitalize on local sample diversity while maintaining global quality standards.

In Europe, Middle East and Africa, a diverse mosaic of biobanking ecosystems is taking shape. European nations benefit from pan-national consortia that harmonize protocols, data privacy regulations and operational benchmarks, creating scalable repositories accessible to multinational research teams. Meanwhile, several Middle Eastern countries are bolstering infrastructure investments to advance national genomics agendas and public health surveillance. Across Africa, partnerships with international research organizations are catalyzing the development of population-scale biobanks aimed at understanding disease dynamics within underrepresented cohorts. Despite challenges related to funding models and logistic complexities, this region presents significant opportunities for collaborative innovation and capacity building.

Asia-Pacific exhibits rapid expansion driven by government-led precision health programs and a burgeoning biotechnology sector. Leading economies such as China, Japan and Australia have established sophisticated biobank networks integrated with hospital systems and research institutes, reinforcing translational research pipelines. In parallel, India and Southeast Asian nations are scaling sample collection and processing capabilities to support large-scale cohort studies. Stakeholders in this region are prioritizing regulatory harmonization, digital transformation of laboratory workflows and localized manufacturing of critical consumables. Consequently, Asia-Pacific is poised to become a strategic growth arena, shaping global biobanking trends and best practices.

Leading Biobanking Innovators Driving Technological Advancements Commercial Strategies and Collaborative Ventures Transforming Sample Storage Analytical and Logistics Solutions

Industry leaders have demonstrated a clear commitment to advancing biobanking through targeted investments in automation, informatics and strategic collaborations. For instance, one prominent instrumentation provider has enhanced cryogenic storage automation by integrating robotics with cloud-based monitoring systems, enabling real-time alerts and predictive maintenance. Another specialist in molecular sample preparation has expanded its portfolio to include comprehensive data analytics solutions that streamline workflow optimization and regulatory reporting. These technology providers are setting new standards for specimen integrity and operational transparency.

Meanwhile, a leading automation firm has deployed high-throughput liquid handling platforms capable of processing thousands of samples per day, reducing manual intervention and accelerating study timelines. An established laboratory systems supplier has fortified its software suite, embedding laboratory information management functionalities that support chain-of-custody tracking, consent management and multi-site collaboration. Complementing these efforts, several emerging biotech companies are focusing on modular cold chain consumables designed to maintain ultra-low temperature stability during long-distance shipments.

Additionally, several agile startups are challenging incumbent players by developing niche solutions such as lab-on-chip sample stabilization and blockchain-based provenance tracking. These disruptive entrants emphasize modularity and interoperability, compelling established companies to accelerate innovation cycles and integrate open-architecture frameworks. This dynamic competitive landscape underscores the value of continuous R&D investments and adaptive business models.

Moreover, strategic partnerships and mergers have reshaped the competitive landscape. Major corporations have acquired niche informatics firms to bolster their end-to-end biobanking offerings, while others have forged alliances with academic consortia to pilot decentralized storage models. These corporate maneuvers underscore a broader trend toward integrated solutions designed to address the diverse needs of research institutions, clinical laboratories and pharmaceutical developers alike.

Actionable Roadmap for Biobanking Stakeholders to Enhance Operational Efficiency Foster Innovation Strengthen Regulatory Compliance and Expand Strategic Collaborations

To maintain a competitive edge in the evolving biobanking arena, industry leaders should prioritize the adoption of advanced automation and digitalization technologies. Implementing robotic storage and retrieval systems, coupled with centralized analytics platforms, can enhance throughput while minimizing human error. In addition, integrating machine learning tools to predict equipment maintenance and streamline sample tracking will reinforce operational resilience.

Concurrently, organizations must reinforce their regulatory and ethical frameworks by establishing transparent consent management processes and adhering to emerging international standards. Developing modular compliance protocols that can be adapted to new jurisdictions will reduce administrative overhead and facilitate cross-border research collaborations.

Fostering partnerships across research institutions, service providers and technology vendors will unlock synergies and accelerate innovation. Joint ventures and consortia can pool resources for large-scale studies, enabling access to diverse specimen collections and sharing best practices in specimen handling and data governance.

Furthermore, procurement strategies should emphasize supply chain diversification and local sourcing of critical equipment and consumables. By cultivating relationships with multiple vendors and exploring nearshoring options, biobanking operations can mitigate the impact of tariff fluctuations and logistical disruptions.

Prioritizing robust cybersecurity measures and data interoperability standards is equally important. Biobanking leaders should establish encrypted data exchanges and adopt universal metadata schemas to facilitate seamless collaboration. This emphasis on secure and harmonized data flows will further strengthen trust among partners and enhance the scalability of cross-institutional research programs.

Finally, continuous skills development remains vital. Investing in targeted training programs for technical staff and data managers will ensure that organizations can effectively leverage new technologies and maintain high standards of sample integrity and data quality.

Robust Research Methodology Integrating Qualitative and Quantitative Approaches Primary Data Collection and Rigorous Validation Processes Ensuring Reliability and Depth

The research methodology underpinning this report combines both qualitative and quantitative approaches to deliver comprehensive and unbiased insights. Initial secondary research involved an extensive review of academic literature, industry publications and regulatory guidelines to establish a foundational understanding of current biobanking practices and emerging trends. This desk research informed the development of primary research instruments and interview protocols.

Primary data collection was conducted through in-depth interviews with leading practitioners, equipment manufacturers, service providers and regulatory experts. These discussions provided nuanced perspectives on operational challenges, technology adoption and strategic priorities. In parallel, an online survey targeted a broad cross-section of end users to capture quantitative data on sample type preferences, storage requirements and budgetary allocations.

Data triangulation was achieved by cross-verifying information from multiple sources, ensuring that findings reflect a consistent and accurate industry narrative. Key metrics and thematic insights were validated through iterative expert reviews, enabling adjustments to interpretation and emphasis based on peer feedback. Statistical analysis techniques, including trend mapping and correlation assessments, further enriched the robustness of the conclusions.

The research methodology also incorporated a thorough review of ethical frameworks and data privacy regulations. Potential limitations related to respondent bias and geographic representation were mitigated through purposive sampling and weighting adjustments. Ethical considerations guided the design of interview questions and data handling protocols, ensuring anonymity and compliance with global human subject research standards.

Overall, the methodology was designed to balance depth and breadth, combining granular field-level observations with high-level trend analysis. This hybrid approach ensures that the resulting strategic recommendations and market insights are both actionable and grounded in empirical evidence.

Concluding Reflections on Biobanking Evolution Emphasizing Strategic Imperatives Collaborative Innovations and Future-Ready Solutions Shaping the Research Landscape

As the biobanking sector continues to evolve, it remains a cornerstone of translational research and precision medicine endeavors. The convergence of advanced storage technologies, informatics platforms and service-oriented models has reshaped traditional workflows, enabling more efficient and reliable specimen management. Moreover, the integration of virtual repositories and decentralized networks has expanded collaborative horizons, fostering innovation across research communities.

Regulatory realignments and tariff dynamics further underscore the need for agile operational strategies. By embracing diversified procurement configurations and strengthening cross-border logistics frameworks, organizations can safeguard supply continuity and maintain high standards of sample viability. Meanwhile, segmentation insights reveal that a comprehensive understanding of product offerings, biobank typologies, specimen categories, application areas and end-user needs is essential for designing tailored solutions that drive scientific progress.

Regional analysis highlights distinct geographical opportunities, from established hubs in North America and Europe to rapidly emerging markets in Asia-Pacific and strategic growth corridors across the Middle East and Africa. Concurrently, leading companies are demonstrating how targeted investments in automation, analytics and strategic partnerships can unlock new value propositions.

Ultimately, thriving biobanking ecosystems will depend on continuous innovation, inclusive governance structures and adaptive business models. Collaborative innovation hubs and public-private consortia will play pivotal roles in translating scientific discoveries into scalable solutions. Embracing a culture of transparency, shared learning and technological agility will be key to sustaining momentum as the field advances.

Looking forward, the path to sustainable biobanking excellence will hinge on balancing operational efficiency with ethical governance, fostering collaborative ecosystems and continuously innovating through technology adoption. These strategic imperatives offer a clear roadmap for stakeholders seeking to advance research capabilities and deliver impactful outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biobanking Market, by Offering

  • 8.1. Product
    • 8.1.1. Biobanking Equipment
      • 8.1.1.1. Automated Sample Storage Systems
      • 8.1.1.2. Cryogenic Storage Systems
      • 8.1.1.3. Incubators & Centrifuges
      • 8.1.1.4. Refrigerators & Freezers
      • 8.1.1.5. Sample Transport & Packaging Units
    • 8.1.2. Consumables
  • 8.2. Services
    • 8.2.1. Consent & Regulatory Compliance Services
    • 8.2.2. Data Management & Bioinformatics
    • 8.2.3. Sample Collection & Processing Services
    • 8.2.4. Sample Storage Services
    • 8.2.5. Sample Transport & Logistics
  • 8.3. Software

9. Biobanking Market, by Biobank Type

  • 9.1. Physical Biobanks
  • 9.2. Virtual Biobanks

10. Biobanking Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Serum
    • 10.1.3. Whole Blood
  • 10.2. Cells
  • 10.3. DNA/RNA
  • 10.4. Tissue

11. Biobanking Market, by Application

  • 11.1. Diagnostics & Therapeutics
  • 11.2. Drug Discovery & Clinical Research

12. Biobanking Market, by End User

  • 12.1. Academic & Research Institutions
  • 12.2. Contract Research Organizations (CROs)
  • 12.3. Government & Public Health Agencies
  • 12.4. Hospitals & Clinical Labs
  • 12.5. Pharmaceutical & Biotech Companies

13. Biobanking Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biobanking Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biobanking Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biobanking Market

17. China Biobanking Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ASKION GmbH
  • 18.6. Avantor, Inc.
  • 18.7. Azenta Life Sciences, Inc.
  • 18.8. BioKryo
  • 18.9. BioLife Solutions, Inc.
  • 18.10. Charles River Laboratories International, Inc.
  • 18.11. Cryoport Systems, LLC
  • 18.12. Cureline, Inc.
  • 18.13. FIND
  • 18.14. Firalis Molecular Precision
  • 18.15. Greiner Bio-One International GmbH
  • 18.16. Hamilton Company
  • 18.17. LGC Biosearch Technologies
  • 18.18. Merck KGaA
  • 18.19. PHC Corporation
  • 18.20. Qiagen N.V.
  • 18.21. Sampled
  • 18.22. Sopachem BV
  • 18.23. SPT Labtech Ltd
  • 18.24. STEMCELL Technologies Inc.
  • 18.25. Taylor-Wharton
  • 18.26. Tecan Trading AG
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. US Biolab Corporation, Inc.
  • 18.29. VigiSolvo

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOBANKING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOBANKING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOBANKING MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOBANKING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOBANKING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOBANKING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOBANKING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOBANKING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOBANKING MARKET SIZE, BY PRODUCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOBANKING MARKET SIZE, BY PRODUCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOBANKING MARKET SIZE, BY PRODUCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOBANKING MARKET SIZE, BY AUTOMATED SAMPLE STORAGE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOBANKING MARKET SIZE, BY AUTOMATED SAMPLE STORAGE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOBANKING MARKET SIZE, BY AUTOMATED SAMPLE STORAGE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOBANKING MARKET SIZE, BY CRYOGENIC STORAGE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOBANKING MARKET SIZE, BY CRYOGENIC STORAGE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOBANKING MARKET SIZE, BY CRYOGENIC STORAGE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOBANKING MARKET SIZE, BY INCUBATORS & CENTRIFUGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOBANKING MARKET SIZE, BY INCUBATORS & CENTRIFUGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOBANKING MARKET SIZE, BY INCUBATORS & CENTRIFUGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOBANKING MARKET SIZE, BY REFRIGERATORS & FREEZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOBANKING MARKET SIZE, BY REFRIGERATORS & FREEZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOBANKING MARKET SIZE, BY REFRIGERATORS & FREEZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & PACKAGING UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & PACKAGING UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & PACKAGING UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOBANKING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOBANKING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOBANKING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOBANKING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOBANKING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOBANKING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOBANKING MARKET SIZE, BY CONSENT & REGULATORY COMPLIANCE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOBANKING MARKET SIZE, BY CONSENT & REGULATORY COMPLIANCE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOBANKING MARKET SIZE, BY CONSENT & REGULATORY COMPLIANCE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOBANKING MARKET SIZE, BY DATA MANAGEMENT & BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOBANKING MARKET SIZE, BY DATA MANAGEMENT & BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOBANKING MARKET SIZE, BY DATA MANAGEMENT & BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE COLLECTION & PROCESSING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE COLLECTION & PROCESSING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE COLLECTION & PROCESSING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE STORAGE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE STORAGE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE STORAGE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & LOGISTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & LOGISTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TRANSPORT & LOGISTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOBANKING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOBANKING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOBANKING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOBANKING MARKET SIZE, BY PHYSICAL BIOBANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOBANKING MARKET SIZE, BY PHYSICAL BIOBANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOBANKING MARKET SIZE, BY PHYSICAL BIOBANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOBANKING MARKET SIZE, BY VIRTUAL BIOBANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOBANKING MARKET SIZE, BY VIRTUAL BIOBANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOBANKING MARKET SIZE, BY VIRTUAL BIOBANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOBANKING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOBANKING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOBANKING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOBANKING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOBANKING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOBANKING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOBANKING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOBANKING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOBANKING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOBANKING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOBANKING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOBANKING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOBANKING MARKET SIZE, BY CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOBANKING MARKET SIZE, BY CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOBANKING MARKET SIZE, BY CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOBANKING MARKET SIZE, BY DNA/RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOBANKING MARKET SIZE, BY DNA/RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOBANKING MARKET SIZE, BY DNA/RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOBANKING MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOBANKING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOBANKING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOBANKING MARKET SIZE, BY DIAGNOSTICS & THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOBANKING MARKET SIZE, BY DIAGNOSTICS & THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOBANKING MARKET SIZE, BY DIAGNOSTICS & THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOBANKING MARKET SIZE, BY DRUG DISCOVERY & CLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOBANKING MARKET SIZE, BY DRUG DISCOVERY & CLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOBANKING MARKET SIZE, BY DRUG DISCOVERY & CLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOBANKING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOBANKING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOBANKING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOBANKING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOBANKING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOBANKING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOBANKING MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOBANKING MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOBANKING MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOBANKING MARKET SIZE, BY HOSPITALS & CLINICAL LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOBANKING MARKET SIZE, BY HOSPITALS & CLINICAL LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOBANKING MARKET SIZE, BY HOSPITALS & CLINICAL LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOBANKING MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOBANKING MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOBANKING MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOBANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BIOBANKING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOBANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 198. GCC BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 199. GCC BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 200. GCC BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. GCC BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 204. GCC BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 228. G7 BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 229. G7 BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 230. G7 BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. G7 BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 234. G7 BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. G7 BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. NATO BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 238. NATO BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 239. NATO BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 240. NATO BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. NATO BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. NATO BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 244. NATO BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)